Lutetium-177 (Lu-177) Market Research Report 2022: Pipeline Focuses on Lu-177 labeled mABs and Peptides for Various Indications that are in Clinical Trials, and FDA and CE-Approved Products
28 Jun 2022
AntibodyCollaborate
DUBLIN, June 28, 2022 /PRNewswire/ -- The "Lutetium-177 (Lu-177) Global Market and Pipeline Analysis - Forecast to 2028" report has been added to
ResearchAndMarkets.com's offering.
Lutetium-177 (Lu-177) Global Market and Pipeline Analysis - Forecast to 2028" gives comprehensive insights on the various Lu-177 based drugs being developed for the treatment of prostate cancer, NETs, Lung cancer, solid tumors and other conditions.
The report covers marketed product details and also drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on Lu-177 labeled monoclonal antibodies and peptides for various indications that are in clinical trials, and FDA and CE-approved products.
The report covers the patient population, treatment cost, total addressable market and penetration analysis for GEP-NET and Prostate cancer. It covers a list of nuclear reactors that have the potential to produce Lu-177 both medium and high flux reactors with their locations all over the world. It also focuses on supply chain analysis and market dynamics (DROT) of Lu-177.
This report enables Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stakeholders to identify and analyze the available licensing/collaborative commercial opportunities in the Lu-177 global market.
The report also provides strategic insights on some of the molecules which will eventually be launched in the next few years.
In market analysis section, global GEP-NET and Prostate cancer market are indicated along with the Lu-177 therapy market size, eligible patients pool, total addressable market (TAM), market penetration, opportunity and demand for Lu-177 isotope is forecasted from 2019 to 2026.
Lu-177 players and their production capacities
Lu-177 market dynamics.
Lu-177 related deals analysis.
Global, N.A., Europe, APAC and RoW prevalence rates (GEP-NET & Prostate cancer).
Pipeline Analysis
Pipeline Analysis based molecule type
Pipeline Analysis based on indications
Pipeline analysis based on targets
Monoclonal Antibodies labeled pipeline analysis
Peptide labeled pipeline analysis
Pipeline analysis based on leading players & their molecule analysis
Key Players Analysis
The key player's analysis section provides an in-depth understanding of various companies working on Lu-177 and their pipelines with development phase as well as understanding partnering strategies such as deals entered by the company.
Global key players overview
Global key players Pipeline data (discovery, pre-clinical & clinical development)
Global key players deal (collaborations, partnership, licensing agreements, grants, funding etc.)
Key Topics Covered:
1. Report Description
2. Introduction
4. Market Dynamics (DROT)
5. Supply Chain Analysis
Direct
Indirect
6. Supply Chain Updates
U.S. DMF Filing Details
7. Lu-177 Annual Estimated Production Capacity In Ci (Selected Reactors)
8. Production Cost Of Direct/Indirect Method
9. Deals
Agreement
Partnership
Collaboration
10. Market Data
TAM and Penetration - GEP-NET (Region)
TAM -Prostate Cancer (Region)
11. Assumptions
12. Pipeline Analysis
Development Stage
Indications
Targets
Molecule Type
13. RIT Based Pipeline Analysis
By Phase
By Indication
By Target
Pipeline Analysis
Clinical trial update on Phase 3 and Phase 2b molecules
14. PRRT Based Pipeline Analysis
By Phase
By Indication
By Target
Pipeline Analysis
Clinical trial update on Phase 3
15. Major Players
ITM Isotopen Ag
16. Medium Flux Reactor and Location
17. High Flux Reactor and Location
18. References
For more information about this report visit https://www.researchandmarkets.com/r/pmkjsg
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.